Impact of fluvastatin slow-release on low-density lipoprotein subfractions in patients with type 2 diabetes: baseline low-density lipoprotein profile determines specific mode of action  by Winkler, Karl et al.
JACC March 6, 2002 
1058-95 Reproducibility of High Resolution Magnetic Resonance 
Imaging for In Vivo Monitoring of Atherosclerotic 
Lesions in Humans 
Roberto Corti, Zahi A. Fayad, Valentin Fuster, Frank Macaluso, Juan J. Badimon, 
Cardiovascular Biology Research Laboratory. Cardiovascular/nstitute.Mount Sinai 
School of Medicine, New York, New York. 
Background: MRI allows the in-viva sequential monitoring of human atherosclorotic 
lesions. The purpose of this study was to investigate the reproducibility of non-invasive 
MRI for in viva quantification of human atherosclerotic lesions. 
Method: Two consecutive independent scans of the thoracic aorta and carotid arteries 
were performed in 9 asymptomatic hypercholesterolemic patients. MRI was performed 
using high-resolution black-blood technique. Special attention was given to match MRI of 
the aortic (n=9) and carotid (n=7) plaques using several anatomical landmarks. Lumen 
area (LA), total vascular area (TVA) and vessel wall area (VWA=TVA-LA) were calcu- 
lated by computer-assisted tracing of cross-sectional vessel images. The image specific 
error (ISE) was defined as the absolute difference in the tracing of matched images. Per- 
centage error = (ISE/mean of 2 tracings)*100%. 
Results: Aortic Lesions: The mean LA was 462±143mm2 with a VWA of 245±66 mm2. 
The absolute ISE when measuring VWA was 11±8 ram2; however when the average 
measurement of 5 sections were considered, the error was markedly reduced to a 6±4 
ram2 corresponding to an error of 2.4±1.7%. 
Carotid Lesion: The mean I_A was 34±10mm2 with a VWA of 48±18 ram2. The absolute 
ISE when measuring VWA was 3±3 ram2; however when the average measurement of 5 
sections were considered, the error was markedly reduced to a 1±1 ram2 corresponding 
to an error of 3.0±2.5%. 
Based on the reported data on reproducibility changes in plaque size of more than 5% for 
aortic and 7% for carotids (corresponding to 2*SD) considering the average of 5 contigu- 
ous images for comparison, will be "real" and accurately detected by MRI. 
Conclusions: High-resolution MRI allows the precise and reproducible assessment of 
human atheroscleretic lesions in viva which is needed for monitoring sequential changes 
in plaque size and to study the effectiveness of different treatments (vg. lipid-lowering) in 
follow-up studies. 
1058-96 Atheroeclerotic Plaques, Inflammation, and Thoracic 
Aortic Dilatation: Insights From a Population-Based 
Transesophageal Echocardiographic Study With 
Implications for Aortic Aneurysm Formation 
Yoram Aamon, Bijoy K. Khandheria, Irene Meissner, Gary L. Schwartz, JoRean D. Sicks, 
Angels Fought, W. M. O'Fallon, David O. Wiebers, James B. Seward, A. J. Tajik, Mayo 
Clinic and Mayo Foundation, Rochester, Minnesota. 
Backoround: We hypothesized that aortic dilatation is an atherosclerosis-related process. 
Methods: Thoracic aortic dimensions (diameters at the sinuses of Valsalva [SV], ascend- 
ing aorta [AA], aortic arch and descending aorta [DA]) were measured by transesobh- 
ageal echocardiography in 373 subjects (median age 66 yr, range 51-101; 52% men) 
participating in a population-based study (Stroke Prevention: Assessment of Risk in a 
Community), who were free of significant aortic valve disease. The associations between 
aortic atherosclerotic plaques, markers of inflammation (high-sensitivity C-reactive pro- 
tein [hs-CRP] and fibrinogen) and aortic dimensions were examined. Results: Age, male 
gender and body surface area (BSA) were significant determinants of aortic diameters. 
Adjusting for these variables: 1) Thick plaques in the AA (greater or equal to 4 mm) were 
negatively associated with SV diameter (P=-0.03); AA plaques were not associated with 
AA diameter; 2) The presence of aortic arch plaques (of any degree) and thick arch 
plaques (greater or equal to 4 mm) were associated with increased arch diameter (1.41 
mm increase in diameter [.t0.53] in the presence of plaques, P=0.007; 2.18 mm increase 
in diameter ~1.11] in the presence of thick plaques, P=0.05); 3) The presence of DA 
plaques and greater DA plaque thickness were associated with increased DA diameter 
(1.51 mm increase in diameter ~0.53] in the presence of plaques, P=0.004; 0.18 mm 
increase in diameter ~.0.08] per mm increase in plaque thickness, P=-0.03). Adjusting for 
age, gender, BSA and smoking status, hs-CRP and fibrinogen were not significantly 
associated with aortic dimensions (all P values >0.05). Cooclusioo~: Aortic atheroscle- 
rotic plaques are associated with distal, but not proximal, aortic dilatation. These findings 
support the hypothesis that atherosclerotic weakening of the vessel wall plays a role in 
aortic dilatation and, possibly, in aortic aneurysm formation. Systemic inflammatory mark- 
ers are not associated with aortic dimensions, suggesting that non-inflammatory athero- 
sclerotic processes are involved in aortic dilatation, 
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1059-73 Fasting Blood Glucose in the Nondiabetic Range Is a 
Continuous and Graded Risk Factor for CHD 
Byron J, Hoogwerf, Dennis L. Sorecher. Gregory L. Pearce, Joseph P, Frolkis, Monica 
Acevedo, Donald G. Vidt, The Cleveland Clinic Foundation, Cleveland, Ohio. 
Background: Diabetes mellitus (DM) and impaired glucose tolerance are associated 
with several CHD risk factors (RF's) and a >2 fold risk for CHD. Few data exist on 
whether glucose levels in the non-diabetic range are associated with risk for CHD when 
adjusted for multiple risk factors. Objective: We studied the relationships among fasting 
blood glucose (FBG) <126 rag/alL, prevalent CHD, traditional CHD RF's (obesity, dyslipi- 
demia, BP), Framingham risk score and non-traditional CHD RF's (Lp(a), fibrinogen, 
homooysteine (tHcy)) in 2440 consecutive patients without known DM at high risk for 
CHD in a Preventive Cardiology Clinic. Results: There was a trend toward increasing 
values across glucose quintiles for age (P<0.00t), BMt (P<0.001), systolic BP (P<0.001), 
fibrinogen (P<0.001), tHcy (P<0.001). There was a trend for decreasing values for HDL-c 
(P<0.001), as well as for % current smokers (P = 0.02) and Lp(a) (P<0.001). The preva- 
lence of CHD, Framingham risk score and odds ratio (OR) for CHD risk whether unad- 
justed, adjusted for traditional RF's or adjusted for Framingham risk score plus non- 
traditional RF's is significant for the top 3 quintites compare to the lowest (Table). Con° 
cluslons: FBG levels in the non-diabetic range are associated with several traditional 
risk factors for CHD (age, BMI, BP, HDL-c) as well as fibrinogen and tHcy. The OR for 
CHD increases as a continuous function of glucose whether unadjusted or fully adjusted 
for RF's. 
*p<0.001 
Glucose Quintile 1 II III IV V P 
FBG (mg/dL) <_79 80-86 87-92 93-99 100-125 <0.001 
CHD (%) 43 47 53 56 65 <0.001 
Pramingham Risk Score 4.4 5.0 5.3 5.5 6.3 <0.001 
OR (Adjusted all risk factors) 1.0 1.16 1.52* 1.80" 2.78 <0.001 
1059-74 Impact of Fluvaatatin Slow-Release on Low-Density 
Lipoprotein Subfractions in Patients With Type 2 
Diabetes: Baseline Low-Density Lipoprotein Profile 
Determines Specific Mode of Action 
Karl Winkier, Michael M. Hoffmann, Isolde Friedrich, Rita Gl~iser, Claudia Abletshauser, 
Manfred W. Baumstark, Heinrich Wieland, Winfried M~rz, Division of Clinical Chemist~ 
Department of Medicine, Albert Ludwigs Universi~ Freiburg, Germany, Novartis Pharma 
GmbH, NEimberg, German~ 
Background: Patients with type 2 diabetes have an increased coronary artery disease 
risk and lipid metabolism characterized by increased triglycerides, decreased high-den- 
sity Iipoprotein (HDL) cholesterol, and slightly elevated low-density lipoprotein (LDL) cho- 
lesterol. They also have a preponderance of atherogenic dense LDL (dLDL). We 
therefore studied the effect of slow-release (XL) fluvastatin on LDL subfractions in 89 
patients with type 2 diabetes. 
Methods: After a 4-week dietary run-in period, this multicenter, double blind, random- 
ized, parallel-group study compared fluvastatin XL 80 mg (n = 42) with placebo (n = 47), 
given once daily for 8 weeks to patients (mean age: 67 years; range: 39-89 years) with 
mean baseline triglycedde, LDL cholesterol, and HDL cholesterol levels of 211, 154, and 
44.6 mg/dL, respectively. Lipoproteins were isolated by sequential preparative ultracen- 
trifugation and total LDL was separated into 6 subfractions by equilibrium density gradi- 
ent ultraoentrifugation. 
Results: Fluvastatin decreased mean baseline LDL cholesterol (-32%, p<0.001), triglyc- 
erides (-18%, p<O.001), and dLDL (LDL-5: -27%, p<0.001 and LDL-6: -22%, p<0.001), 
these changes being statistically significant compared with placebo. The HDL cholesterol 
increase (3.1%) was not significant, but reached +18% in patients with a baseline HDL 
below 35 mg/dL (n = 10). A baseline dLDL preponderance (apoB in LDL-5 + LDL-6>25 
mg/dL) was present in 3/4 of patients. In these patients, fluvastatin decreased all LDL 
subfractions significantly from baseline (13.7-29.3%), absolute and relative reductions in 
dLDL being greatest. In patients with no baseline dLDL (apoB in LDL-5 + LDL-6<25 mg/ 
dL) only LDL-1 to LDL-3 were significantly reduced, dLDL remaining unchanged. 
Conclusions: Fluvastatin 80 mg XL effectively lowers LDL cholesterol, triglyceddes, and 
dLDL in patients with type 2 diabetes. Fluvastatin also decreases specifically those LDL- 
subfractions that are increased in type 2 diabetes, with or without a predominance of 
dLDL. The antiatherogenic potential of fluvastatin in patients with type 2 diabetes may 
thus be greater than expected from its effects on LDL cholesterol and triglycerides alone. 
1059-75 Ef fect  of Simvastatin on Insulin Resistance and Beta 
Cell Function in Hypercholesterolemic Patients 
Nuri Haksev•r, Fikret Ilgenli, Mustafa Demirci, Go/cuk Naval Hospital Endocrinology, 
Cardiology and Biochemistry Clinics, Kocae/i, Turkey 
Background: The effects of statins on insulin resistance (IR) and I~ celt function ([~cf) are 
not clearly determined. 
Methods: Hypercholesterolemic 113 patients (cholesterol level>200mg/dl, mean age 
53.1±13.5 years) were studied to assess the effect of simvastatin. They were divided in 
